FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab

INTRODUCTION: Targeting costimulatory receptors of the tumor necrosis factor receptor (TNFR) superfamily with agonistic antibodies is a promising approach in cancer immuno therapy. It is known that their efficacy strongly depends on FcγR cross-linking. METHODS: In this study, we made use of a Jurkat...

Descripción completa

Detalles Bibliográficos
Autores principales: Leitner, Judith, Egerer, Ricarda, Waidhofer-Söllner, Petra, Grabmeier-Pfistershammer, Katharina, Steinberger, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413977/
https://www.ncbi.nlm.nih.gov/pubmed/37575254
http://dx.doi.org/10.3389/fimmu.2023.1208631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413977/
https://www.ncbi.nlm.nih.gov/pubmed/37575254
http://dx.doi.org/10.3389/fimmu.2023.1208631

Ejemplares similares